Skip to main content
SpringerLink
Log in

Alemtuzumab/selenium

Marine-Lenhart syndrome, Graves' ophthalmopathy and lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Le Moli R, et al. Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis. Hormones 20: 161-165, No. 1, Mar 2021. Available from: URL: http://doi.org/10.1007/s42000-020-00215-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab/selenium. Reactions Weekly 1880, 28 (2021). https://doi.org/10.1007/s40278-021-04862-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-04862-1

Search

Navigation